Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02255032 · ClinicalTrials.gov registry record · Phase 2

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

A Phase 2 study of Uveitis and Macular Edema, sponsored by Clearside Biomedical.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target
11
Study locations

NCT02255032 is a Phase 2 study of Uveitis and Macular Edema that has completed, run by Clearside Biomedical. The registered enrollment target is 22 participants, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02255032, a Phase 2 study of Uveitis and Macular Edema, has completed, sponsored by Clearside Biomedical.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target
11
Study locations

Study Summary

The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis. A single suprachoroidal injection of one of two doses of CLS-TA will each be evaluated in subjects with macular edema following non-infectious uveitis.

Conditions Studied

Uveitis Macular Edema Uveitis, Posterior Uveitis, Intermediate Uveitis, Anterior Panuveitis

Interventions

  • DRUG 4 mg CLS-TA
  • DRUG 0.8 mg CLS-TA

Study Locations (11)

Massachusetts

  • - Boston
  • - Waltham

Florida

  • - Miami

Georgia

  • - Atlanta

Illinois

  • - Chicago

Nebraska

  • - Omaha

New York

  • - New York

North Carolina

  • - Winston-Salem

North Dakota

  • - Fargo

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2014-10
Est. Completion 2016-01
Phase Phase 2

Sponsor

Clearside Biomedical

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02255032

The ClinicalTrials.gov registry entry for NCT02255032 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (96% lower). The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which 4 mg CLS-TA is the first listed.

NCT02255032 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Massachusetts, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT02255032 about?

NCT02255032 is a clinical study titled "Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis". The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis. A single suprachoroidal injection of one of two doses of CLS-TA will each be evaluated in subjects with macular edema following non-infectiou...

What is the current status of trial NCT02255032?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-10. Estimated completion is 2016-01.

What conditions does trial NCT02255032 study?

This clinical trial studies the following conditions: Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Intermediate, Uveitis, Anterior.

What interventions are being tested in trial NCT02255032?

The interventions under investigation include: 4 mg CLS-TA (DRUG), 0.8 mg CLS-TA (DRUG).

Who is sponsoring clinical trial NCT02255032?

This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02255032 being conducted?

This trial has 11 study locations across Florida, Georgia, Illinois, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uveitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Uveitis

All registered trials for this condition

Macular Edema

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.